Earnings Call · Q2 FY2022·2022-08-13

Q2 22EPS +25.00%·Rev n/aQ1 22EPS 0.00%·Rev n/aQ4 21EPS +56.10%·Rev n/aQ3 21EPS -100.00%*·Rev n/a⚠ consensus missing

MiNK Therapeutics, Inc. INKT

Kimberly Ha — Investor Relations

Jennifer Buell — Chief Executive Officer

Christine Klaskin — Chief Financial Officer

−2.9%1d on move date−2.5% vs SPY3d+23.5%5d+150.0%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more INKT calls or request research access.

More INKT calls Browse calls Request research access